1695 related items for PubMed ID: 20542736
1. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B.
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[Abstract] [Full Text] [Related]
2. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M.
Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
[Abstract] [Full Text] [Related]
3. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
Sorensen PS, Lycke J, Erälinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmeström C, Stenager E, Sellebjerg F, Sondergaard HB, SIMCOMBIN study investigators.
Lancet Neurol; 2011 Aug; 10(8):691-701. PubMed ID: 21742556
[Abstract] [Full Text] [Related]
4. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[Abstract] [Full Text] [Related]
5. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[Abstract] [Full Text] [Related]
6. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW, CHOICE investigators.
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[Abstract] [Full Text] [Related]
7. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, CARE-MS I investigators.
Lancet; 2012 Nov 24; 380(9856):1819-28. PubMed ID: 23122652
[Abstract] [Full Text] [Related]
8. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A, ADVANCE Study Investigators.
Lancet Neurol; 2014 Jul 24; 13(7):657-65. PubMed ID: 24794721
[Abstract] [Full Text] [Related]
9. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L, TOWER Trial Group.
Lancet Neurol; 2014 Mar 24; 13(3):247-56. PubMed ID: 24461574
[Abstract] [Full Text] [Related]
10. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, Hauser SL.
Lancet; 2011 Nov 19; 378(9805):1779-87. PubMed ID: 22047971
[Abstract] [Full Text] [Related]
11. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Lancet; 1998 Nov 07; 352(9139):1498-504. PubMed ID: 9820297
[Abstract] [Full Text] [Related]
12. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L, FREEDOMS study group.
Lancet Neurol; 2012 May 07; 11(5):420-8. PubMed ID: 22494956
[Abstract] [Full Text] [Related]
13. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B, REGARD study group.
Lancet Neurol; 2008 Oct 07; 7(10):903-14. PubMed ID: 18789766
[Abstract] [Full Text] [Related]
14. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA, CARE-MS II investigators.
Lancet; 2012 Nov 24; 380(9856):1829-39. PubMed ID: 23122650
[Abstract] [Full Text] [Related]
15. Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial.
Gonsette RE, Sindic C, D'hooghe MB, De Deyn PP, Medaer R, Michotte A, Seeldrayers P, Guillaume D, ASIIMS study group.
Mult Scler; 2010 Apr 24; 16(4):455-62. PubMed ID: 20200198
[Abstract] [Full Text] [Related]
16. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
N Engl J Med; 2006 Mar 02; 354(9):911-23. PubMed ID: 16510745
[Abstract] [Full Text] [Related]
17. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
[Abstract] [Full Text] [Related]
18. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V.
Mult Scler; 2010 Apr 26; 16(4):450-4. PubMed ID: 20150398
[Abstract] [Full Text] [Related]
19. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ, Figgitt DP.
CNS Drugs; 2004 Apr 26; 18(6):379-96. PubMed ID: 15089110
[Abstract] [Full Text] [Related]
20. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, TRANSFORMS Study Group.
Lancet Neurol; 2011 Jun 26; 10(6):520-9. PubMed ID: 21571593
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
